Expertise in
1
conditions

Dr. Sarika Jain

General Surgery
Office
11175 Campus St Rm 21121, 
Loma Linda, CA 
Expertise in
1
conditions
Office
11175 Campus St Rm 21121, 
Loma Linda, CA 

Overview

Sarika Jain is a General Surgeon practicing medicine in Loma Linda, California.

Dr. Jain is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Arterial Embolism, and Heart Bypass Surgery.

She is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 10 clinical trials.

Specialties

General Surgery

Licenses

Thoracic Surgery (Cardiothoracic Vascular Surgery) in CA

Hospital Affiliations

Providence St Mary Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

Office
11175 Campus St Rm 21121, Loma Linda, CA 92350
Other Locations
Pomona Valley Cardiac Surgery
160 E Artesia St Ste 355, Pomona, CA 91767

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)
I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Carboplatin, Pembrolizumab
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Enrollment Status: Completed
Publish Date: June 12, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Nivolumab, Veliparib
Study Phase: Phase 1
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
Enrollment Status: Terminated
Publish Date: July 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 2
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Enrollment Status: Unknown
Publish Date: July 13, 2020
Intervention Type: Other, Drug, Biological
Study Drugs: Capecitabine, Pembrolizumab
Study Phase: Phase 2
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Enrollment Status: Terminated
Publish Date: November 20, 2018
Intervention Type: Biological, Other
Study Phase: Phase 2
View 9 Less Clinical Trials

18 Total Publications

Intracardiac echocardiography from coronary sinus.
Intracardiac echocardiography from coronary sinus.
Journal: Journal of cardiovascular electrophysiology
Published: July 08, 2022
Similar Doctors
Expertise in
16
conditions
Dr. Alfred A. Simental
General Surgery
Expertise in
16
conditions
Dr. Alfred A. Simental
General Surgery
Referral may be required

Loma Linda Univ Anesthesiology Medical Group Inc

11234 Anderson St, 
Loma Linda, CA 
 (0.2 miles away)
909-558-2824
Languages Spoken:
English
See accepted insurances

Alfred Simental is a General Surgeon practicing medicine in Loma Linda, California. Dr. Simental is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Thyroid Cancer, Hyperparathyroidism, Anaplastic Thyroid Cancer, Thyroidectomy, and Parathyroidectomy.

Expertise in
20
conditions
Dr. John C. Lipham
General Surgery
Expertise in
20
conditions
Dr. John C. Lipham
General Surgery
Referral may be required

Los Angeles-Plastic Surgery

1450 San Pablo St Ste 6200, 
Los Angeles, CA 
 (54.4 miles away)
323-442-6868
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Lipham is a General Surgeon practicing medicine in Los Angeles, California. Dr. Lipham is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Hiatal Hernia, Hernia, Endoscopy, and Gastrectomy.

Expertise in
17
conditions
Dr. Ahmed M. Abou-Zamzam
General Surgery
Expertise in
17
conditions
Dr. Ahmed M. Abou-Zamzam
General Surgery
Referral may be required

Loma Linda University Faculty Medical Clinics-Ear Nose And Throat Surgery

11370 Anderson St Ste 2100, 
Loma Linda, CA 
 (0.1 miles away)
909-558-2840
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ahmed Abou-Zamzam is a General Surgeon practicing medicine in Loma Linda, California. Dr. Abou-Zamzam is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Carotid Artery Disease, Peripheral Artery Disease, Arterial Embolism, Aneurysm Repair, and Carotid Artery Surgery.

Frequently Asked Questions about Dr. Sarika Jain

How do I make an appointment with Dr. Sarika Jain?

You can book an appointment with Dr. Sarika Jain by calling their office at 909-558-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sarika Jain a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sarika Jain is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sarika Jain specialize in?

While Dr. Sarika Jain is a General Surgery, they have specific expertise in Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Heart Bypass Surgery. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Surgery.

Does Dr. Sarika Jain participate in research or clinical trials?

Yes. Dr. Sarika Jain has published 18 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Sarika Jain's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sarika Jain accept my insurance?

Dr. Sarika Jain accepts most major insurance plans, including Humana and Medicaid. We recommend calling the office directly at 909-558-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile